What SEC filings does Corvus Pharmaceuticals, Inc. submit to the SEC?

Corvus Pharmaceuticals, Inc. (CRVS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CRVS?

A Form 4 for CRVS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Corvus Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CRVS?

The 10-K is Corvus Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CRVS SEC filings directly on EDGAR?

You can view all historical Corvus Pharmaceuticals, Inc. filings on the SEC EDGAR company page for CRVS. Each filing card on this page links directly to the original SEC document.

How often does Corvus Pharmaceuticals, Inc. file with the SEC?

Corvus Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CRVS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CRVS SEC Filing News — Corvus Pharmaceuticals, Inc.

Latest SEC filings for Corvus Pharmaceuticals, Inc. (CRVS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-06.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid…

Sector: Healthcare Industry: Biotechnology Market Cap: $818.5M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CRVS currently lean bullish. Of the 20 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 8 insider transactions (Form 4) in this period.

CRVS Filing Activity Snapshot 2026-01-23 — 2026-08-06

Insider Transactions (Form 4)

2 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$250.2K

Moore David Scott (Director) · 2026-06-15

21,700 shares · Form 4

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Corvus Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 5 compensation award, 2 open-market purchase and 1 option exercise. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×5: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Open-market purchase Insider Buying 2026-06-15

CRVS insider Moore David Scott (Director) bought 21,700 shares (~$250.2K)

Moore David Scott, listed as Director at Corvus Pharmaceuticals, Inc., reported an open-market purchase of 21,700 CRVS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	21,700	$11.53	$250.2K
`A`	Compensation award derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Moore David Scott (Director) Shares: 21,700 Est. Value: $250.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

CLARK IAN T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: CLARK IAN T (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

Grais Linda (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Grais Linda (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

Thompson Peter A. (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Thompson Peter A. (Director, 10% Owner)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

van den Broek Richard (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: van den Broek Richard (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-20

CRVS insider MILLER RICHARD A MD (Director, President and CEO) bought 6,932 shares (~$83.5K)

MILLER RICHARD A MD, listed as Director, President and CEO at Corvus Pharmaceuticals, Inc., reported an open-market purchase of 6,932 CRVS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	5,000	$12.05	$60.2K
`P`	Open-market purchase	1,932	$12.01	$23.2K

Filing: Form 4 (Insider Transaction) Insider: MILLER RICHARD A MD (Director, President and CEO) Shares: 6,932 Est. Value: $83.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-27

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

Chan Andrew C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (Right to Buy)	30,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Chan Andrew C. (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-01-30

CRVS insider Form 4 filed for equity award, exercise, or tax withholding

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	30,000	$15.00	$450.0K
`M`	Option exercise	15,000	$9.70	$145.5K
`M`	Option exercise	15,000	$12.50	$187.5K
`M`	Option exercise	15,000	$3.61	$54.1K
`M`	Option exercise	15,000	$2.00	$30.0K
`M`	Option exercise	15,000	$3.27	$49.0K
`M`	Option exercise	15,000	$2.74	$41.1K
`M`	Option exercise	15,000	$2.60	$39.0K
`M`	Option exercise	15,000	$0.99	$14.8K
`M`	Option exercise	15,000	$0.96	$14.5K
`M`	Option exercise	15,000	$2.49	$37.4K
`M`	Option exercise	15,000	$1.64	$24.6K
`M`	Option exercise	15,000	$2.12	$31.8K
`M`	Option exercise derivative · Stock Option (Right to Buy)	30,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—
`M`	Option exercise derivative · Stock Option (Right to Buy)	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Thompson Peter A. (Director, 10% Owner) Shares: 210,000

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for Corvus Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-06

CRVS filed 8-K — material company event

Corvus Pharmaceuticals, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.